Konjenital Musküler Distrofiler
Özet
Konjenital musküler distrofiler, erken dönemde ortaya çıkan kas güçsüzlüğü, hipotoni ve kas biyopsisindeki distrofik bulgularla karakterize, heterojen klinik ve genetik özelliklere sahip bir hastalık grubudur. Tanı süreci klinik bulgular, serum kreatin kinaz seviyeleri ve özellikle gelişen genetik analiz yöntemlerine dayanmakta olup, hastalık yapıcı genlerin tanımlanmasıyla sınıflama sürekli güncellenmektedir. Tedavi seçenekleri henüz kısıtlı olsa da, multidisipliner destekleyici yaklaşımlar ve genetik temelli yeni tedavi stratejileri üzerine çalışmalar yoğun şekilde devam etmektedir.
Congenital muscular dystrophies represent a heterogeneous group of disorders characterized by early-onset muscle weakness, hypotonia, and dystrophic findings in muscle biopsies, each with distinct clinical and genetic features. Diagnostic processes rely on clinical evaluation, serum creatine kinase levels, and increasingly advanced genetic analysis, while classifications evolve alongside the identification of new pathogenic genes. Although definitive treatments are currently limited, multidisciplinary supportive care and research into novel genetic-based therapeutic strategies are actively progressing.
Referanslar
Muntoni F, Voit T. The congenital muscular dystrophies in 2004: A century of exciting progress. Neuromuscul Disord. 2004;14(10):635-649. doi:10.1016/j.nmd.2004.06.009
Bertini E, D’Amico A, Gualandi F, Petrini S. Congenital Muscular Dystrophies: A Brief Review. Semin Pediatr Neurol. 2011;18(4):277-288. doi:10.1016/j.spen.2011.10.010
Mercuri E, Pera MC, Brogna C. Neonatal hypotonia and neuromuscular conditions. Handb Clin Neurol. 2019;162:435-448. doi:10.1016/B978-0-444-64029-1.00021-7
Mercuri E, Muntoni F. Congenital Muscular Dystrophies. Second Edi. Elsevier Inc.; 2015. doi:10.1016/B978-0-12-417044-5.00029-9
Norwood FLM, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: In-depth analysis of a muscle clinic population. Brain. 2009;132(11):3175-3186. doi:10.1093/brain/awp236
Darin N, Tulinius M. Neuromuscular disorders in childhood: A descriptive epidemiological study from western Sweden. Neuromuscul Disord. 2000;10(1):1-9. doi:10.1016/S0960-8966(99)00055-3
Hughes MI, Hicks EM, Nevin NC, Patterson VH. The prevalence of inherited neuromuscular disease in Northern Ireland. Neuromuscul Disord. 1996;6(1):69-73. doi:10.1016/0960-8966(94)00017-4
Graziano A, Bianco F, D’Amico A, et al. Prevalence of congenital muscular dystrophy in Italy: A population study. Neurology. 2015;84(9):904-911. doi:10.1212/WNL.0000000000001303
Sframeli M, Sarkozy A, Bertoli M, et al. Congenital muscular dystrophies in the UK population: Clinical and molecular spectrum of a large cohort diagnosed over a 12-year period. Neuromuscul Disord. 2017;27(9):793-803. doi:10.1016/j.nmd.2017.06.008
Ge L, Zhang C, Wang Z, et al. Congenital muscular dystrophies in China. Clin Genet. 2019;96(3):207-215. doi:10.1111/cge.13560
Kang PB, Morrison L, Iannaccone ST, et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of congenital muscular dystrophy. Neurology. 2015;84(13):1369-1378. doi:10.1212/WNL.0000000000001416
Mercuri E, Muntoni F. The ever-expanding spectrum of congenital muscular dystrophies. Ann Neurol. 2012;72(1):9-17. doi:10.1002/ana.23548
Bönnemann CG, Wang CH, Quijano-Roy S, et al. Diagnostic approach to the congenital muscular dystrophies. Neuromuscul Disord. 2014;24(4):289-311. doi:10.1016/j.nmd.2013.12.011
Ravenscroft G, Davis MR, Lamont P, Forrest A, Laing NG. New era in genetics of early-onset muscle disease: Breakthroughs and challenges. Semin Cell Dev Biol. 2017;64:160-170. doi:10.1016/j.semcdb.2016.08.002
Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for α2 chain of laminin). Eur J Hum Genet. 2002;10(2):91-94. doi:10.1038/sj.ejhg.5200743
O’Grady GL, Lek M, Lamande SR, et al. Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. Ann Neurol. 2016;80(1):101-111. doi:10.1002/ana.24687
Geranmayeh F, Clement E, Feng LH, et al. Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord. 2010;20(4):241-250. doi:10.1016/j.nmd.2010.02.001
Oliveira J, Gruber A, Cardoso M, et al. LAMA2 gene mutation update: Toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat. 2018;39(10):1314-1337. doi:10.1002/humu.23599
Abdel Aleem A, Elsaid MF, Chalhoub N, et al. Clinical and genomic characteristics of LAMA2 related congenital muscular dystrophy in a patients’ cohort from Qatar. A population specific founder variant. Neuromuscul Disord. 2020;30(6):457-471. doi:10.1016/j.nmd.2020.03.009
Menezes MJ, McClenahan FK, Leiton C V., Aranmolate A, Shan X, Colognato H. The extracellular matrix protein laminin α2 regulates the maturation and function of the blood–brain barrier. J Neurosci. 2014;34(46):15260-15280. doi:10.1523/JNEUROSCI.3678-13.2014
Philpot J, Cowan F, Pennock J, et al. Merosin-deficient congenital muscular dystrophy: The spectrum of brain involvement on magnetic resonance imaging. Neuromuscul Disord. 1999;9(2):81-85. doi:10.1016/S0960-8966(98)00110-2
Saredi S, Gibertini S, Matalonga L, et al. Exome sequencing detects compound heterozygous nonsense LAMA2 mutations in two siblings with atypical phenotype and nearly normal brain MRI. Neuromuscul Disord. 2019;29(5):376-380. doi:10.1016/j.nmd.2019.04.001
Vainzof M, Richard P, Herrmann R, et al. Prenatal diagnosis in laminin α2 chain (merosin)-deficient congenital muscular dystrophy: A collective experience of five international centers. Neuromuscul Disord. 2005;15(9-10):588-594. doi:10.1016/j.nmd.2005.04.009
Muntoni F, Torelli S, Wells DJ, Brown SC. Muscular dystrophies due to glycosylation defects: Diagnosis and therapeutic strategies. Curr Opin Neurol. 2011;24(5):437-442. doi:10.1097/WCO.0b013e32834a95e3
Hayashi YK, Ogawa M, Tagawa K, et al. Selective deficiency of α-dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology. 2001;57(1):115-121. doi:10.1212/WNL.57.1.115
Godfrey C, Foley AR, Clement E, Muntoni F. Dystroglycanopathies: Coming into focus. Curr Opin Genet Dev. 2011;21(3):278-285. doi:10.1016/j.gde.2011.02.001
Godfrey C, Clement E, Mein R, et al. Refining genotype-phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain. 2007;130(10):2725-2735. doi:10.1093/brain/awm212
Mercuri E, Messina S, Bruno C, et al. Congenital muscular dystrophies with defective glycosylation of dystroglycan: A population study. Neurology. 2009;72(21):1802-1809. doi:10.1212/01.wnl.0000346518.68110.60
Collo G, Starr L, Quaranta V. A new isoform of the laminin receptor integrin α7β1 is developmentally regulated in skeletal muscle. J Biol Chem. 1993;268(25):19019-19024. doi:10.1016/S0021-9258(17)46729-9
Mayer U, Saher G, Fässler R, et al. Absence of integrin α7 causes a novel form of muscular dystrophy. Nat Genet. 1997;17(3):318-323. doi:10.1038/ng1197-318
Nakashima H, Kibe T, Yokochi K. “Congenital muscular dystrophy caused by integrin α7 deficiency.” Dev Med Child Neurol. 2009;51(3):245. doi:10.1111/j.1469-8749.2008.03258.x
Hayashi YK, Chou FL, Engvall E, et al. Mutations in the integrin α7 gene cause congenital myopathy. Nat Genet. 1998;19(1):94-97. doi:10.1038/ng0598-94
Bönnemann CG. The collagen VI-related myopathies: Muscle meets its matrix. Nat Rev Neurol. 2011;7(7):379-390. doi:10.1038/nrneurol.2011.81
Nadeau A, Kinali M, Main M, et al. Natural history of Ullrich congenital muscular dystrophy. Neurology. 2009;73(1):25-31. doi:10.1212/WNL.0b013e3181aae851
Foley AR, Quijano-Roy S, Collins J, et al. Natural history of pulmonary function in collagen VI-related myopathies. Brain. 2013;136(12):3625-3633. doi:10.1093/brain/awt284
Yonekawa T, Komaki H, Okada M, et al. Rapidly progressive scoliosis and respiratory deterioration in Ullrich congenital muscular dystrophy. J Neurol Neurosurg Psychiatry. 2013;84(9):982-988. doi:10.1136/jnnp-2012-304710
Hicks D, Lampe AK, Barresi R, et al. A refined diagnostic algorithm for Bethlem myopathy. Neurology. 2008;70(14):1192-1199. doi:10.1212/01.wnl.0000307749.66438.6d
Konjenital U, Distrofinin M, Tanısı P, et al. Özgün Araştırma Original Article.; 2018.
Brockington M, Brown SC, Lampe A, et al. Prenatal diagnosis of Ullrich congenital muscular dystrophy using haplotype analysis and collagen VI immunocytochemistry. Prenat Diagn. 2004;24(6):440-444. doi:10.1002/pd.902
Fu J, Zheng YM, Jin SQ, et al. “Target” and “sandwich” signs in thigh muscles have high diagnostic values for collagen VI-related myopathies. Chin Med J (Engl). 2016;129(15):1811-1816. doi:10.4103/0366-6999.186638
Mercuri E, Lampe A, Allsop J, et al. Muscle MRI in Ullrich congenital muscular dystrophy and Bethlem myopathy. Neuromuscul Disord. 2005;15(4):303-310. doi:10.1016/j.nmd.2005.01.004
Arbogast S, Beuvin M, Fraysse B, Zhou H, Muntoni F, Ferreiro A. Oxidative stress in SEPN1-related myopathy: From pathophysiology to treatment. Ann Neurol. 2009;65(6):677-686. doi:10.1002/ana.21644
Moghadaszadeh B, Topaloglu H, Merlini L, et al. Genetic heterogeneity of congenital muscular dystrophy with rigid spine syndrome. Neuromuscul Disord. 1999;9(6-7):376-382. doi:10.1016/S0960-8966(99)00051-6
Villar-Quiles RN, von der Hagen M, Métay C, et al. The clinical, histologic, and genotypic spectrum of SEPN1-related myopathy: A case series. Neurology. 2020;95(11):e1512-e1527. doi:10.1212/WNL.0000000000010327
Hankiewicz K, Carlier RY, Lazaro L, et al. Whole-body muscle magnetic resonance imaging in SEPN1-related myopathy shows a homogeneous and recognizable pattern. Muscle and Nerve. 2015;52(5):728-735. doi:10.1002/mus.24634
Mercuri E, Muntoni F. The ever-expanding spectrum of congenital muscular dystrophies. Ann Neurol. 2012;72(1):9-17. doi:10.1002/ana.23548
Fan Y, Tan D, Song D, et al. Clinical spectrum and genetic variations of LMNA -related muscular dystrophies in a large cohort of Chinese patients. J Med Genet. 2021;58(5):326-333. doi:10.1136/jmedgenet-2019-106671
Mitsuhashi S, Ohkuma A, Talim B, et al. A congenital muscular dystrophy with mitochondrial structural abnormalities caused by defective de novo phosphatidylcholine biosynthesis. Am J Hum Genet. 2011;88(6):845-851. doi:10.1016/j.ajhg.2011.05.010
Haliloglu G, Talim B, Sel CG, Topaloglu H. Clinical characteristics of megaconial congenital muscular dystrophy due to choline kinase beta gene defects in a series of 15 patients. J Inherit Metab Dis. 2015;38(6):1099-1108. doi:10.1007/s10545-015-9856-2
O’Grady GL, Best HA, Oates EC, et al. Recessive ACTA1 variant causes congenital muscular dystrophy with rigid spine. Eur J Hum Genet. 2015;23(6):883-886. doi:10.1038/ejhg.2014.169
Helbling DC, Mendoza D, McCarrier J, et al. Severe neonatal RYR1 myopathy with pathological features of congenital muscular dystrophy. J Neuropathol Exp Neurol. 2019;78(3):283-287. doi:10.1093/jnen/nlz004
Shamseldin HE, Bennett AH, Alfadhel M, Gupta V, Alkuraya FS. GOLGA2, encoding a master regulator of golgi apparatus, is mutated in a patient with a neuromuscular disorder. Hum Genet. 2016;135(2):245-251. doi:10.1007/s00439-015-1632-8
Davignon L, Chauveau C, Julien C, et al. The transcription coactivator ASC-1 is a regulator of skeletal myogenesis, and its deficiency causes a novel form of congenital muscle disease. Hum Mol Genet. 2016;25(8):1559-1573. doi:10.1093/hmg/ddw033
Wiessner M, Roos A, Munn CJ, et al. Mutations in INPP5K, Encoding a Phosphoinositide 5-Phosphatase, Cause Congenital Muscular Dystrophy with Cataracts and Mild Cognitive Impairment. Am J Hum Genet. 2017;100(3):523-536. doi:10.1016/j.ajhg.2017.01.024
Wang CH, Bonnemann CG, Rutkowski A, et al. Consensus statement on standard of care for congenital muscular dystrophies. J Child Neurol. 2010;25(12):1559-1581. doi:10.1177/0883073810381924
Yilmaz ÖT, Karaduman AA. Nöromusküler Hastalıklarda Fizyoterapi Yaklaşımları. Türkiye Klin Fiz Tıp ve Rehabil - Özel Konular. 2010;3(3):26-33. Accessed July 1, 2021. https://www.turkiyeklinikleri.com/article/tr-noromuskuler-hastaliklarda-fizyoterapi-yaklasimlari-59321.html
Dowling JJ, D. Gonorazky H, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: The future is now. Am J Med Genet Part A. 2018;176(4):804-841. doi:10.1002/ajmg.a.38418
Yurchenco PD, McKee KK, Reinhard JR, Rüegg MA. Laminin-deficient muscular dystrophy: Molecular pathogenesis and structural repair strategies. Matrix Biol. 2018;71-72:174-187. doi:10.1016/j.matbio.2017.11.009
Barraza-Flores P, Bates CR, Oliveira-Santos A, Burkin DJ. Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics. Front Mol Neurosci. 2020;13(February):1-9. doi:10.3389/fnmol.2020.00001
Dowling JJ, D. Gonorazky H, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: The future is now. Am J Med Genet Part A. 2018;176(4):804-841. doi:10.1002/ajmg.a.38418
Sawnani H, Mayer OH, Modi AC, et al. Randomized trial of lung hyperinflation therapy in children with congenital muscular dystrophy. Pediatr Pulmonol. 2020;55(9):2471-2478. doi:10.1002/ppul.24954
Moulin M, Ferreiro A. Muscle redox disturbances and oxidative stress as pathomechanisms and therapeutic targets in early-onset myopathies. Semin Cell Dev Biol. 2017;64:213-223. doi:10.1016/j.semcdb.2016.08.003
Vannoy CH, Leroy V, Lu QL. Dose-Dependent Effects of FKRP Gene-Replacement Therapy on Functional Rescue and Longevity in Dystrophic Mice. Mol Ther - Methods Clin Dev. 2018;11:106-120. doi:10.1016/j.omtm.2018.10.004
Kemaladewi DU, Maino E, Hyatt E, et al. Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism. Nat Med. 2017;23(8):984-989. doi:10.1038/nm.4367
